Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
November 01, 2022 09:10 ET
|
Myriad Genetics, Inc.
$67.5 million tuck-in acquisition strengthens Myriad’s Women’s Health portfolio of prenatal productsFast-growing SneakPeek test has helped 750,000 parents learn baby’s gender from home – earliest...
Myriad Genetics Reports Third Quarter Financial Results
November 01, 2022 09:05 ET
|
Myriad Genetics, Inc.
Highlights: Revenue of $156.4 million for the quarter ended September 30, 2022. Third quarter revenue, excluding divested businesses, was impacted by currency translations ($3.3...
Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
October 31, 2022 16:30 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today the election of Paul M. Bisaro to its...
Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022
October 26, 2022 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third-quarter earnings conference call on...
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
September 28, 2022 09:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey it conducted...
Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com câncer de mama na pré-menopausa
August 31, 2022 08:00 ET
|
Myriad Genetics, Inc.
O teste EndoPredict, da Myriad Genetics, identificou com precisão mulheres na pré-menopausa com câncer de mama ER+, HER2- que poderiam evitar, com segurança, a quimioterapia adjuvante SALT LAKE CITY,...
Nuevo estudio publicado en Clinical Cancer Research Journal destaca el uso de la prueba EndoPredict para informar el tratamiento en pacientes premenopáusicas con cáncer de mama
August 31, 2022 08:00 ET
|
Myriad Genetics, Inc.
La prueba EndoPredict de Myriad Genetics identificó con precisión a mujeres premenopáusicas con cáncer de mama ER+, HER2- que podrían evitar la quimioterapia adyuvante de forma segura SALT LAKE CITY,...
Un nuovo studio pubblicato sulla rivista Clinical Cancer Research mette in evidenza l’impiego del test EndoPredict per indicare quale trattamento adottare in pazienti con tumore al seno in premenopausa
August 31, 2022 08:00 ET
|
Myriad Genetics, Inc.
Il test EndoPredict di Myriad Genetics ha identificato in modo accurato le donne in premenopausa con carcinoma mammario ER+, HER2- che potevano con sicurezza evitare la chemioterapia adiuvante SALT...
Neue Studie, im Clinical Cancer Research Journal veröffentlicht, unterstreicht die Bedeutung des EndoPredict-Tests zur Information über die Behandlung von prämenopausalen Brustkrebs-Patientinnen
August 31, 2022 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics’ EndoPredict-Test identifiziert präzise prämenopausale Frauen mit ER+, HER2-Brustkrebs, die eine adjuvante Chemotherapie vermeiden können SALT LAKE CITY, Aug. 31, 2022 (GLOBE...
Une nouvelle étude publiée dans le Clinical Cancer Research Journal met en avant l’utilisation du test EndoPredict pour éclairer les décisions thérapeutiques chez les patientes préménopausées atteintes d’un cancer du sein
August 31, 2022 08:00 ET
|
Myriad Genetics, Inc.
Le test EndoPredict de Myriad Genetics identifie avec précision les femmes préménopausées atteintes d'un cancer du sein RE+, HER2- qui pourraient éviter une chimiothérapie adjuvante sans perte de...